Cargando…

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma

The therapeutic responses of many solid tumours to chemo- and radio-therapies are far from fully effective but therapies targeting malignancy-related cellular changes show promise for further control. In head and neck squamous cell carcinoma, the epidermal growth factor receptor (EGFR) is commonly o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Setúbal Destro Rodrigues, Maria Fernanda, Gammon, Luke, Rahman, Muhammad M., Biddle, Adrian, Nunes, Fabio Daumas, Mackenzie, Ian C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862593/ https://www.ncbi.nlm.nih.gov/pubmed/29568372 http://dx.doi.org/10.18632/oncotarget.24416

Ejemplares similares

Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma
por: Siqueira, Juliana Mota, et al.
Publicado: (2023)

Mechanisms of immune evasion by head and neck cancer stem cells
por: Xavier, Flávia Caló Aquino, et al.
Publicado: (2022)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

The Stem Cell Marker Bmi-1 Is Sensitive in Identifying Early Lesions of Carcinoma ex Pleomorphic Adenoma
por: Sedassari, Bruno Tavares, et al.
Publicado: (2015)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
por: Stanam, Aditya, et al.
Publicado: (2016)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

GLI3 knockdown decreases stemness, cell proliferation and invasion in oral squamous cell carcinoma
por: Rodrigues, Maria Fernanda Setúbal Destro, et al.
Publicado: (2018)

Phenotypic Plasticity Determines Cancer Stem Cell Therapeutic Resistance in Oral Squamous Cell Carcinoma
por: Biddle, Adrian, et al.
Publicado: (2016)

Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report
por: Thinn, Mie Mie, et al.
Publicado: (2019)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
por: Liu, Shuli, et al.
Publicado: (2020)

Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment
por: Goh, Kah Yee, et al.
Publicado: (2022)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism
por: Pickhard, Anja, et al.
Publicado: (2014)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2019)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma
por: Kondo, T, et al.
Publicado: (2016)

FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Mu, Lan, et al.
Publicado: (2022)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
por: Sobhakumari, Arya, et al.
Publicado: (2016)

Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
por: Ngan, Hoi-Lam, et al.
Publicado: (2020)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
por: Schmitz, Sandra, et al.
Publicado: (2015)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

Retracted: FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Healthcare Engineering, Journal of
Publicado: (2023)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
por: Jain, Ankit P., et al.
Publicado: (2019)

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
por: Akmansu, Muge, et al.
Publicado: (2010)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
por: Saigal, Kunal, et al.
Publicado: (2014)

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)
por: Seiwert, T. Y., et al.
Publicado: (2014)

MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma
por: Bozec, Alexandre, et al.
Publicado: (2017)

Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
por: Tang, Wen-Hua, et al.
Publicado: (2020)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vkacu1vdl40f2hgid2efb72j7d